Contract notice
Section I: Contracting
authority
I.1) Name and addresses
THE UNIVERSITY OF BIRMINGHAM
RC000645
Edgbaston
BIRMINGHAM
B152TT
UK
Contact person: Kseniya Samsonik
E-mail: K.Samsonik@bham.ac.uk
NUTS: UKG31
Internet address(es)
Main address: https://www.birmingham.ac.uk/
I.3) Communication
The procurement documents are available for unrestricted and full direct access, free of charge at:
www.in-tendhost.co.uk/universityofbirmingham/aspx/Home
Additional information can be obtained from the abovementioned address
Tenders or requests to participate must be sent electronically to:
www.in-tendhost.co.uk/universityofbirmingham/aspx/Home
I.4) Type of the contracting authority
Body governed by public law
I.5) Main activity
Education
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
Tender for the Supply of Services - Independent Central Review Of Primary Outcome Data For The GLO-BHNL Platform Clinical Trial - University Of Birmingham
Reference number: SC12106/23
II.1.2) Main CPV code
85150000
II.1.3) Type of contract
Services
II.1.4) Short description
The University of Birmingham invites tenders for independent central review of the primary outcome data for the clinical platform trial, Glo-BNHL. The platform aims to test a wide range of therapies over its lifetime in order to find better treatments for the rare paediatric cancer, B-cell non-Hodgkin's Lymphoma. The design allows addition of new treatment arms as novel therapies become available for testing. There are currently 2 treatment arms.
Independent central review of the clinical data that informs the primary outcome measures is required, to include: cross sectional imaging by CT or MRI, PET-CT scan, bone marrow aspirate, bone marrow trephine and lumbar puncture pathology reports.
Glo-BNHL is an international trial with participating sites in the UK, Europe, USA, Canada, Australia, New Zealand and Israel. A total of 45 sites will participate, with international sites' activity coordinated by 15 National Coordinating Centres.
Glo-BNHL recently received ethics approval in the UK and will open later this year. Approval in the other participating nations will follow. An expedient solution to independent central review is therefore required.
This project may be funded by the European Regional Development Fund (ERDF) or;
- European Structural and Investment Fund (ESIF) or;
- Research Councils UK (RCUK), the strategic partnership of the UK's seven Research Councils.
Please refer to Appendix A via www.in-tendhost.co.uk/universityofbirmingham/aspx/Home for full specification of requirements.
II.1.5) Estimated total value
Value excluding VAT:
5 000 000.00
GBP
II.1.6) Information about lots
This contract is divided into lots:
No
II.2) Description
II.2.3) Place of performance
NUTS code:
UKG3
II.2.4) Description of the procurement
The University of Birmingham invites tenders for independent central review of the primary outcome data for the clinical platform trial, Glo-BNHL. The platform aims to test a wide range of therapies over its lifetime in order to find better treatments for the rare paediatric cancer, B-cell non-Hodgkin's Lymphoma. The design allows addition of new treatment arms as novel therapies become available for testing. There are currently 2 treatment arms.
Independent central review of the clinical data that informs the primary outcome measures is required, to include: cross sectional imaging by CT or MRI, PET-CT scan, bone marrow aspirate, bone marrow trephine and lumbar puncture pathology reports.
Glo-BNHL is an international trial with participating sites in the UK, Europe, USA, Canada, Australia, New Zealand and Israel. A total of 45 sites will participate, with international sites' activity coordinated by 15 National Coordinating Centres.
Glo-BNHL recently received ethics approval in the UK and will open later this year. Approval in the other participating nations will follow. An expedient solution to independent central review is therefore required.
This project may be funded by the European Regional Development Fund (ERDF) or;
- European Structural and Investment Fund (ESIF) or;
- Research Councils UK (RCUK), the strategic partnership of the UK's seven Research Councils.
Please refer to Appendix A via www.in-tendhost.co.uk/universityofbirmingham/aspx/Home for full specification of requirements.
II.2.5) Award criteria
Criteria below:
Quality criterion: Compliance to the Specifications
/ Weighting: 45
Quality criterion: After Sales and Technical back up
/ Weighting: 15
Quality criterion: Delivery and Training
/ Weighting: 15
Quality criterion: Sustainability and Environmental
/ Weighting: 10
Quality criterion: Standard Supplier Questionnaire (SQ) Part 1 and Part 2
/ Weighting: 10
Price
/ Weighting:
5
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
30/03/2024
End:
30/03/2031
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Open procedure
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
IV.2) Administrative information
IV.2.2) Time limit for receipt of tenders or requests to participate
Date:
15/12/2023
Local time: 12:00
IV.2.4) Languages in which tenders or requests to participate may be submitted
EN
IV.2.7) Conditions for opening of tenders
Date:
15/12/2023
Local time: 12:01
Section VI: Complementary information
VI.1) Information about recurrence
This is a recurrent procurement:
No
VI.4) Procedures for review
VI.4.1) Review body
University of Birmingham
Birmingham
UK
VI.5) Date of dispatch of this notice
15/11/2023